temozolomide has been researched along with Hypergonadotropic Hypogonadism in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients." | 5.05 | Prolactinomas in males: any differences? ( Duskin-Bitan, H; Shimon, I, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wildemberg, LE | 1 |
| Fialho, C | 1 |
| Gadelha, MR | 1 |
| Duskin-Bitan, H | 1 |
| Shimon, I | 1 |
2 reviews available for temozolomide and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
Prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon | 2021 |
Prolactinomas in males: any differences?
Topics: Cabergoline; Dopamine Agonists; Humans; Hypogonadism; Male; Pituitary Neoplasms; Prolactinoma; Somat | 2020 |